Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 3/20 | 0.43 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.43 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 16/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23619909 | 0.92 | KCNJ6 (0.45) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL23619903 | 0.91 | KCNJ5 (0.46) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL23619750 | 0.87 | KCNJ5 (0.48) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL23619937 | 0.86 | KCNJ5 (0.48) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL23619907 | 0.83 | KCNJ5 (0.45) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL23619941 | 0.82 | KCNJ5 (0.48) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL25221139 | 0.80 | KCNJ5 (0.50) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL29810340 | 0.80 | KCNJ5 (0.50) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL23448637 | 0.80 | KCNJ5 (0.50) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA | |
| SCHEMBL23619784 | 0.78 | KCNJ5 (0.48) | KCNJ6KCNJ5KCNJ3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| EP-4079724-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021136238-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | 武汉朗来科技发展有限公司 | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | P2RX4, P2RX3, P2RX2 | KCNJ6 494/4885KCNJ5 316/4885KCNJ3 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.